11:33 AM EDT, 05/15/2024 (MT Newswires) -- Celldex Therapeutics ( CLDX ) said Wednesday that the first patient has been dosed in a phase 2 subcutaneous study of barzolvolimab in prurigo nodularis, a chronic skin disease that causes hard, intensely itchy lumps to form on the skin.

The trial will evaluate the efficacy and safety profile of two dose levels of barzolvolimab compared with placebo in about 120 patients with moderate to severe prurigo nodularis, the company said.

Shares of Celldex Therapeutics ( CLDX ) rose past 3% in recent trading activity.

Price: 40.79, Change: +1.32, Percent Change: +3.34